A research team at Lund University in Sweden has discovered a certain type of cell—foam cells—in patients with the aggressive ...

Researchers have identified potential drug targets in glioblastoma cancer stem cells, providing a new approach to treat this ...

A team led by researchers at the University of Toronto has uncovered new targets that could be the key to effectively ...

Glioblastoma is the most common and deadliest form of brain cancer. Patients face a bleak prognosis—the average survival after diagnosis is between 12 and 15 months. And just 6.9% of patients survive ...

A team led by researchers at the University of Toronto has uncovered new targets that could be the key to effectively ...

Phase 3 trial results showed that adding veliparib to temozolomide did not significantly improve overall or progression-free survival in newly diagnosed, MGMT-hypermethylated glioblastoma.

The initial trio of patients with glioblastoma have begun treatment with ropidoxuridine in a phase 2 clinical trial, ...

A pioneering research study announced today (October 23) will trial multiple new treatments for people in the UK living with ...

A new clinical trial for patients with recurrent glioblastoma brain cancer has opened at UCLH, with leadership and support ...

New cancer trial is a ‘lifeline’, says 62-year-old Paul Read who would’ve had less than a year to live due to agressive brain ...

Ropidoxuridine (IPdR) is Shuttle Pharma's lead candidate radiation sensitizer for use in combination with RT to treat brain tumors (glioblastoma), a deadly malignancy of the brain with no known cure.

CNS Pharmaceuticals (NASDAQ: CNSP) , focused on innovative cancer therapies for brain and central nervous system cancers, recently participated in ...